Product Launch (Blog)

Feb, 28 2023

How is the Increasing Preference of Cell-Based Assays Bolstering the Growth of the Global Cell Based Assays Market?

Drug discovery research has made considerable use of cell-based therapeutic screening assays to select promising drug candidates from a sizable compound library. These tests cover a wide range of topics and have a variety of variables that can be taken into account throughout any stage of the drug development process. A favorable environment for industrial expansion is projected to be provided by the growing breakthroughs in drug discovery. For instance, in September 2022, scientists at the Fraunhofer Institute created Proxidrugs as a potential treatment for infections, cancer and Alzheimer's disease. It uses a cells-based waste disposal system.

According to Data Bridge Market Research the Cell Based Assays Market accounted for USD 18.9 billion in 2021, and expected to reach USD 32.96 billion by 2029. The market is expected to grow with a CAGR of 7.2% in the forecast period of 2022 to 2029.

“Growing Preference for Cell-Based Assays Across Healthcare Will Aid Growth”

Unlike biochemical experiments, they provide constant tissue-specific responses in a physiologically realistic milieu. The pharmaceutical and biotechnology companies are also utilizing cell-based assays as part of their lead discovery and optimization processes for drug development, which is the main driver fueling this market's expansion. Additionally, the likelihood of disease outbreaks (such as the COVID-19 and swine flu) increasing as well as an increase in research activities are predicted to drive market expansion. The market's expansion is additionally anticipated to be tempered by the cheap costs of labour and raw materials as well as the rising number of CROs offering drug discovery services.

What restraints the growth of Cell Based Assays Market?

“High Costs of Instruments Are Expected to Hamper the Market's Growth”

The overall cost of producing biopharmaceuticals has scaled up significantly due to the usage of these pricey methods. The market is likely to have stagnant growth as a result of low return on investments (ROI) because of the instrumentation's high cost and poor adaptability.

Segmentation: Cell Based Assays Market

The cell based assays market is segmented on the basis of type, product and services, technology, application, end user and distribution channel. 

  • On the basis of type, the cell based assays market is segmented into cell viability assay, cytotoxicity assay, cell death assay, cell proliferation assay and others.
  • On the basis of product and services, the cell based assays market is segmented into consumables, services, instruments and software.
  • On the basis of technology, the cell based assays market is segmented into flow cytometry, high throughput screening, high content screening and label free detection.
  • On the basis of application, the cell based assays market is segmented into drug discovery, basic research and others.
  • On the basis of end user, the cell based assays market is bifurcated into pharmaceutical and biotechnology companies, contract research organizations, academic and research institutions, government organizations and others.
  • On the basis of distribution channel, the cell based assays market is bifurcated into direct and indirect.

Regional Insights: North America is expected to dominate the Cell Based Assays Market

North America is expected to dominate the market due to the rapid growth in the development and usage of cell-based assays in the region, as well as the increased awareness of these assays for drug discovery.

In addition, the Asia-Pacific region is likely to register highest growth rate during the forecast period of 2022 to 2029 due to the use of strategic methods such joint efforts to create drug candidates, rising government expenditure in research and development, and expanding infrastructure growth in the region.

To know more about the study visit,

Recent Developments in Cell Based Assays Market

  • In December 2020, Thermo Fisher Scientific, the industry leader in providing services to science, acquired Phitonex, Inc., a business that invented a spectral dye platform for high-resolution biology applications intended to speed up research and development in cell therapy, immuno-oncology, and immunology research. Thermo Fisher will be able to fulfil evolving customer expectations in protein and cell analysis research by being able to provide more flow cytometry and image multiplexing capabilities as a result of Phitonex's product line.

The Prominent Key Players Operating in the Cell Based Assays Market Include:

  • Danaher (U.S.)
  • Thermo Fisher Scientific (U.S.)
  • Merck KGaA (Germany)
  • BD (U.S.)
  • General Electric (U.S.)
  • PerkinElmer, Inc. (U.S.)
  • Promega Corporation (U.S.)
  • Charles River Laboratories (U.S.)
  • Cell Signaling Technology, Inc. (U.S.)
  • Lonza (Switzerland)
  • BioAgilytix Labs (U.S.)
  • Cisbio (U.S.)
  • Reaction Biology (U.S.)
  • Lebermuth, Inc. (U.S.)
  • Eurofins DiscoverX Products (U.S.)
  • AAT Bioquest, Inc. (U.S.)

Above are the key players covered in the report, to know about more and exhaustive list of cell based assays    market companies contact,

Research Methodology: Global Cell Based Assays Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.

Client Testimonials